Crewe Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Crewe Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-16	Closed	-$97	–	617
2023 Q3	$97	Buy	+16	New	+$131	﹤0.01%	569

Other funds holding ORIC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Crewe Advisors's ORIC Position: Q4 2023 in Review

Crewe Advisors sold out of Oric Pharmaceuticals (ORIC) in Q4 2023, closing a stake of 16 shares — an estimated $97 sold.

Crewe Advisors first reported a position in ORIC in Q3 2023 and held it in 1 quarter. The position peaked at $97 in Q3 2023. 92 funds tracked by Wall St. Rank hold ORIC as of Q4 2023.

Crewe Advisors reported no remaining Oric Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Crewe Advisors sold 16 Oric Pharmaceuticals shares in Q4 2023, an estimated $97.
Crewe Advisors first reported a position in Oric Pharmaceuticals in Q3 2023 and held it in 1 quarter.
Crewe Advisors's Oric Pharmaceuticals position peaked at $97 in Q3 2023.
92 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2023.

Based on Crewe Advisors's 13F filing for Q4 2023, filed 9 Feb 2024.